Gastrointestinal inflammation: A central component of mucosal defense and repair

Experimental Biology and Medicine

Volumn 231, Issue 2, 2006, Pages 130-137

  Martin, Gary R ^a   Wallace, John L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Annexin; Cyclooxygenase; Hydrogen sulfide; Inflammation; Lipoxins; Nitric oxide; Prostaglandins; Ulcer disease

Indexed keywords

AUTACOID; CYTOKINE; ICOSANOID; LIPOXIN; NITRIC OXIDE; POLYAMINE DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTEINASE ACTIVATED RECEPTOR;

BIOSYNTHESIS; DIGESTION; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG TARGETING; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SECRETION; HOST RESISTANCE; HUMAN; INFLAMMATION; MEDIATOR; NONHUMAN; SHORT SURVEY; TISSUE REPAIR;

EID: 32244447306     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100202     Document Type: Short Survey

References (91)

1. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASEB J 10:731-740, 1996.
2. Paimela H, Goddard PJ, Silen W. Present views on restitution of gastrointestinal epithelium. Dig Dis Sci 40:2495-2496, 1995.
3. Hoffmann P, Mazurkiewicz J, Holtmann G, Gerken G, Eysselein VE, Goebell H. Capsaicin-sensitive nerve fibres induce epithelial cell proliferation, inflammatory cell immigration and transforming growth factor-alpha expression in the rat colonic mucosa in vivo. Scand J Gastroenterol 37:414-422, 2002.
4. Holzer P, Livingston EH, Saria A, Guth PH. Sensory neurons mediate protective vasodilatation in rat gastric mucosa. Am J Physiol 260:G363-G370, 1991.
5. Schmidt PT, Lordal M, Gazelius B, Hellstrom PM. Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans. Gut 52:53-56, 2003.
6. Beck PL, McKnight W, Lee SS, Wallace JL. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. Am J Physiol 265:G453-G458, 1993.
7. Ferraz JGP, McKnight W, Sharkey KA, Wallace JL. Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. Gastroenterology 108:1183-1191, 1995.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232-235, 1971.
9. Robert A. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prost Thrombox Res 2:507-520, 1976.
10. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112:1000-1016, 1997.
11. Asako H, Kubes P, Wallace JL, Gaginella T, Wolf RE, Granger DN. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 262:G903-G908, 1992.
12. Asako H, Kubes P, Wallace JL, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 103:146-152, 1992.
13. 2. Biochem Biophys Res Commun 137:404-410, 1986.
14. Kunkel SL, Chensue SW. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Commun 128:892-897, 1985.
15. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 136:186-192, 1986.
16. Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl FA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A 80:4349-4353, 1983.
17. Haurand M, Floh L. Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate. Physiological triggers and modulation by prostanoids. Biochem Pharmacol 38:2129-2137, 1989.
18. 2, dexamethasone, and IL-4. J Immunol 151:2166-2175, 1993.
19. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 88:2692-2696, 1991.
20. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445-454, 1996.
21. Davies NM, Sharkey KA, Asfaha S, Macnaughton WK, Wallace JL. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 11:1101-1108, 1997.
22. Zimmerman KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54:536-540, 1998.
23. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointetinal mucosal defence. Br J Pharmacol 145:275-282, 2005.
24. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:706-714, 2000.
25. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 132:1565-1573, 2001.
26. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharm Exp Ther 300:754-761, 2002.
27. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. Cox-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology 122:1913-1923, 2002.
28. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397, 1997.
29. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 123:795-804, 1998.
30. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2 - implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49:443-453, 2001.
31. Ma L, Del Soldato, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A 99:13243-13247, 2002.
32. Perini RF, Ma L, Wallace JL. Mucosal repair and Cox-2 inhibition. Curr Pharm Res 9:2207-2211, 2003.
33. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123:1598-1606, 2002.
34. Wallace JL, Zamuner SR, McKnight W, Dicay M, Mencarelli A, Del Soldato P, Fiorucci S. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective Cox-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol 286:G76-G81, 2004.
35. Souza MH, De Lima OM, Zamuner SR, Fiorucci S, Wallace JL. Gastritis increases resistance to aspirin-induced mucosal injury via Cox-2-mediated lipoxin synthesis. Am J Physiol 285:G54-G61, 2003.
36. Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, Del Soldato P, Morelli A. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A 100:10937-10941, 2003.
37. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of Cox-2 selective inhibition: a double-blind trial. Gastroenterology 127:395-402, 2004.
38. Serhan CN. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1212:1-25, 1994.
39. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119:512-520, 2000.
40. Wallace JL. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med 19:346-351, 1996.
41. Sanders KM, Ward SM. Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmission Am J Physiol 262:G379-G392, 1992.
42. Marcinkiewicz J, Chain B, Nowak B, Grabowska A, Bryniarski K, Baran J. Antimicrobial and cytotoxic activity of hypochlorous acid: interactions with taurine and nitrite. Inflamm Res 49:280-289, 2000.
43. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 99:607-611, 1990.
44. MacNaughton WK, Cirino G, Wallace JL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 45:1869-1876, 1989.
45. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:173-179, 1994.
46. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257:249-255, 1994.
47. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 96:2711-2718, 1995.
48. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109:524-530, 1995.
49. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 105:1681-1688, 1993.
50. Miller MJS, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, Ye YZ, Rodi CP, Manning PT, Currie MG, Clark DA. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475-1483, 1995.
51. Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 268:G673-G684, 1995.
52. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37:247-255, 1995.
53. Wallace JL, Vergnolle N, Muscara MN, Asfaha S, Chapman K, McKnight W, Del Soldato P, Morelli A, Fiorucci S. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 117:557-566, 1999.
54. Johnson LR, McCormack SA. Healing of gastrointestinal mucosa: involvement of polyamines. News Physiol Sci 14:12-17, 1999.
55. Morgan DML. Polyamines - an overview. Molecular Biotech 11:229-250, 1999.
56. Thomas T, Kiang DT. Additive growth-inhibitory effects of dl-alphadifluoromethylornithine and antiestrogens on Mcf-7 breast-cancer cell-line. Biochem Biophys Res Comm 148:1338-1345, 1987.
57. McCormack SA, Johnson LR. Role of polyamines in gastrointestinal mucosal growth. Am J Physiol 260:G795-G806, 1991.
58. Wang JY, Johnson LR, Tsai YH, Castro GA. Mucosal ornithine decarboxylase, polyamines, and hyperplasia in infected intestine. Am J Physiol 260:G45-G51, 1991.
59. Gobert AP, Cheng YL, Akhtar M, Mersey BD, Blumberg DR, Cross RK, Chaturvedi R, Drachenberg CB, Boucher JL, Hacker A, Casero RA, Wilson KT. Protective role of arginase in a mouse model of colitis. J Immunol 173:2109-2117, 2004.
60. Meleagros L, Ghatei MA, Bloom SR. Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischemia-reperfusion in the rat. Gut 35:1701-1706, 1994.
61. Pillai RB, Tolia V, Rabah R, Simpson PM, Vijesurier R, Lin CH. Increased colonic ornithine decarboxylase activity in inflammatory bowel disease in children. Digest Dis Sci 44:1565-1570, 1999.
62. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Molec Life Sci 58:244-258, 2001.
63. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Research 61:687-693, 2001.
64. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89:2258-2265, 2000.
65. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Proteaseactivated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152, 2001.
66. Uehara A, Muramoto K, Takada H, Sugawara S. Neutrophil serine proteinases activate human nonepithelial cells to produce inflammatory cytokines through protease-activated receptor 2. J Immunol 170:5690-5696, 2003.
67. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 7:207-208, 2005.
68. Vergnolle N, Macnaughton WK, Al-Ani B, Saifeddine M, Wallace JL, Hollenberg MD. Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci U S A 95:7766-7771, 1998.
69. Kawabata A, Kinoshita M, Nishikawa H, Kuroda R, Nishida M, Araki H, Arizono N, Oda Y, Kakehi K. The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 107:1443-1450, 2001.
70. Kawabata A, Nishikawa H, Saitoh H, Nakaya Y, Hiramatsu K, Kubo S, Nishida M, Kawao N, Kuroda R, Sekiguchi F, Kinoshita M, Kakehi K, Arizono N, Yamagishi H, Kawai K. A protective role of proteaseactivated receptor 1 in rat gastric mucosa. Gastroenterology 126:208-219, 2004.
71. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 98:6470-6475, 2001.
72. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 102:216-220, 2005.
73. Chung WO, Hansen SR, Rao D, Dale BA. Protease-activated receptor signaling increases epithelial antimicrobial peptide expression. J Immunol 173:5165-5170, 2004.
74. Playford RJ, Ghosh S. Cytokines and growth factor modulators in intestinal inflammation and repair. J Pathol 250:417-425, 2005.
75. Dinarello CA. Cytokines: interleukin-1 and tumour necrosis factor (cachectin). In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, pp195-208, 1988.
76. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325, 1994.
77. Wallace JL, Keenan CM, Cucala M, Mugridge KG, Parente L. Mechanisms underlying the protective effects of interleukin-1 in experimental NSAID-gastropathy. Gastroenterology 102:1176-1185, 1992.
78. Shibasaki T, Yamauchi N, Hotta M, Imaki T, Oda T, Ling N, Demura H. Interleukin-1 inhibits stress-induced gastric erosion in rats. Life Sci 48:2267-2273, 1991.
79. Wallace JL, Keenan CM, Mugridge KG, Parente L. Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1b. Eur J Pharmacol 186:279-284, 1990.
80. Uehara A, Okumura T, Sekiya C, Okamura K, Takasugi Y, Namiki M. Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. Biochem Biophys Res Commun 162:1578-1584, 1989.
81. Wallace JL, Cucala M, Mugridge K, Parente L. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol 261:G559-G564, 1991.
82. Saperas ES, Yang H, Rivier C, Tache Y. Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Gastroenterology 99:1599-1606, 1990.
83. Wu KK, Sanduja R, Tsai AL, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A 88:2384-2387, 1991.
84. Palmer RM, Hickery MS, Charles IG, Moncada S, Bayliss MT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 193:398-405, 1993.
85. Hogaboam CM, Befus AD, Wallace JL. Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and plateletactivating factor release. J Immunol 151:3767-3774, 1993.
86. Santucci L, Fiorucci S, Di Matteo FM, Morelli A. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 108:393-401, 1995.
87. Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace JL. Tumour necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 270:G42-G48, 1996.
88. Hogaboam CM, Bissonnette EY, Chin BC, Befus AD, Wallace JL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 104:122-129, 1993.
89. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, Mannucci R, del Soldato P, Morelli A. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 116:1089-1106, 1999.
90. Wallace JL, Fiorucci S, Ignarro LJ. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 1:375-382, 2002.
91. Fiorucci S, Santucci L, Gresele P, Faccino RM, del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124:600-607, 2003.